This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics Boosts Health & Wellness, Acquires Provant
by Zacks Equity Research
Quest Diagnostics' (DGX) Provant Health acquisition is in line with its 'accelerate growth' strategy.
Quest Diagnostics Buys PhenoPath, Grows in Anatomic Pathology
by Zacks Equity Research
With the rising need for AP and molecular oncology services in healthcare, we consider the acquisition of PhenoPath by Quest Diagnostics (DGX) to be well-timed and a strategic fit for its portfolio.
Quest Diagnostics Plans a Buyout to Widen TB Testing Suite
by Zacks Equity Research
Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.
Quest Diagnostics Inks Lab Service Deal With ReproSource
by Zacks Equity Research
Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.
Is Quest Diagnostics (DGX) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Quest Diagnostics Grows in Fertility Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.
Here's Why You Should Hold On to Quest Diagnostics (DGX) Now
by Zacks Equity Research
Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.
Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.
Quest Diagnostics (DGX) Posts Inline Q2 Earnings, Revenue Miss
by Urmimala Biswas
Per management, Quest Diagnostics (DGX) made great progress in accelerating growth and driving operational excellence in the reported quarter.
Will 5 Elements Drive Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.
Outpatient Market Gains on Social Awareness: 3 Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.
Why You Should Retain Quest Diagnostics in Your Portfolio
by Zacks Equity Research
Quest Diagnostics (DGX) reveals both sides of the same coin, reflecting its bleak aspects plaguing the stock as well as projecting its brighter side to denote a near-term rebound.
Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?
by Zacks Equity Research
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
Quest Diagnostics (DGX) Q1 Earnings Meet, Guidance Intact
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Quest Diagnostics (DGX) Tops Q1 Earnings, Misses Revenues
by Zacks Equity Research
Quest Diagnostics' (DGX) continues to makes good progress in accelerating growth and driving operational excellence in Q1.
MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE
by Zacks Equity Research
On a positive note, the broader healthcare looks delighted with the massive tax cuts. Also, the scenario within the Medical Device space seems equally bright.
Is a Surprise Coming for Quest Diagnostics (DGX) This Earnings Season?
by Zacks Equity Research
Quest Diagnostics (DGX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings?
by Zacks Equity Research
Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.
Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes?
by Zacks Equity Research
Several FDA clearances within S.E.T since last November raise hope for Zimmer Biomet (ZBH) in Q1.
What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.
WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes
by Zacks Equity Research
The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.
Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.
Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.